BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.